These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 25305049)

  • 1. Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: a pharmacokinetic and pharmacodynamic study.
    Kida K; Shibagaki Y; Tominaga N; Matsumoto N; Akashi YJ; Miyake F; Kimura K
    Clin Pharmacokinet; 2015 Mar; 54(3):273-84. PubMed ID: 25305049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
    Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y
    Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment　- Results From the K-STAR Study.
    Inomata T; Ikeda Y; Kida K; Shibagaki Y; Sato N; Kumagai Y; Shinagawa H; Ako J; Izumi T;
    Circ J; 2017 Dec; 82(1):159-167. PubMed ID: 28835586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy of Tolvaptan in Congestive Heart Failure Patients with and Without Hypoalbuminemia: A Pilot Study.
    Okabe T; Yakushiji T; Igawa W; Ono M; Kido T; Ebara S; Yamashita K; Yamamoto MH; Saito S; Hoshimoto K; Amemiya K; Isomura N; Araki H; Ochiai M
    Cardiovasc Ther; 2015 Oct; 33(5):275-81. PubMed ID: 26122275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III clinical pharmacology study of tolvaptan.
    Inomata T; Izumi T; Matsuzaki M; Hori M; Hirayama A;
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S57-65. PubMed ID: 22120094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T
    Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Matsuzaki M; Hori M; Izumi T; Asanoi H; Tsutamoto T;
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S19-31. PubMed ID: 22120091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolvaptan's Association with Low Risk of Acute Kidney Injury in Patients with Advanced Chronic Kidney Disease and Acute Decompensated Heart Failure.
    Tagaya T; Hayashi H; Ogata S; Takahashi K; Koide S; Inaguma D; Hasegawa M; Yuzawa Y; Tsuboi N
    Am J Nephrol; 2023; 54(7-8):319-328. PubMed ID: 37385233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure.
    Hauptman PJ; Zimmer C; Udelson J; Shoaf SE; Mallikaarjun S; Bramer SL; Orlandi C
    J Cardiovasc Pharmacol; 2005 Nov; 46(5):609-14. PubMed ID: 16220067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
    Hanatani A; Shibata A; Kitada R; Iwata S; Matsumura Y; Doi A; Sugioka K; Takagi M; Yoshiyama M
    Heart Vessels; 2017 Mar; 32(3):287-294. PubMed ID: 27385022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study.
    Matsue Y; Suzuki M; Nagahori W; Yoshida K; Onishi Y; Satoh Y; Ono Y; Nishioka T; Noda M; Sugi K; Torii S; Tejima T; Sakurada H; Yamaguchi S; Okishige K; Fujii H; Takahashi A
    Cardiovasc Drugs Ther; 2014 Feb; 28(1):73-7. PubMed ID: 24048511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolvaptan in a pediatric patient with diuretic-resistant heart and kidney failure.
    Hirano D; Kakegawa D; Yamada A; Ito A; Miwa S; Ida H
    Pediatr Int; 2015; 57(1):183-5. PubMed ID: 25711263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF).
    Ng TMH; Grazette LP; Fong MW; Yoon AJ; Lou M; Kuo A; Upadhyay RY; Han EE; Mehra A; Elkayam U
    ESC Heart Fail; 2020 Aug; 7(4):1927-1934. PubMed ID: 32543020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of tolvaptan add-on treatment on patients with heart failure requiring long-term congestion management: A retrospective cohort study using a medical claim database in Japan.
    Kinugawa K; Matsukawa M; Nakamura Y; Aihara M; Sano H
    J Cardiol; 2023 Jul; 82(1):35-42. PubMed ID: 36587792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure.
    Ikeda S; Ohshima K; Miyazaki S; Kadota H; Shimizu H; Ogimoto A; Hamada M
    ESC Heart Fail; 2017 Nov; 4(4):614-622. PubMed ID: 29154417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction.
    Matsue Y; Ter Maaten JM; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; van der Meer P; Damman K; Voors AA; Goldsmith SR
    Clin Res Cardiol; 2017 Oct; 106(10):802-812. PubMed ID: 28540483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.
    Shoaf SE; Bramer SL; Bricmont P; Zimmer CA
    J Cardiovasc Pharmacol; 2007 Aug; 50(2):213-22. PubMed ID: 17703139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.